Dr. Reddy's Laboratories Limited
RDYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citigroup | upgrade | Sell →Buy | Sep 29, 2026 |
| HSBC | upgrade | Hold →Buy | Jun 5, 2025 |
| Barclays | maintain | Overweight | Nov 6, 2024 |
| Barclays | maintain | Overweight | Jul 30, 2024 |
| Barclays | maintain | Overweight | May 8, 2024 |
| Barclays | maintain | Overweight | Jan 29, 2024 |
| Barclays | maintain | Overweight | Jun 1, 2023 |
| Barclays | maintain | Overweight | Oct 31, 2022 |
| Barclays | maintain | Overweight | Oct 25, 2022 |
| Barclays | maintain | Overweight | Sep 12, 2022 |
| Barclays | maintain | Overweight | Jul 25, 2022 |
| Barclays | maintain | Overweight | May 24, 2022 |
| Barclays | maintain | Overweight | Nov 1, 2021 |
| Barclays | upgrade | Equal Weight →Overweight | Feb 2, 2021 |
| CLSA | maintain | Buy →Outperform | Jan 28, 2020 |
| Citigroup | upgrade | Sell →Buy | Jan 9, 2020 |
| Bank of America | downgrade | Buy →Neutral | Nov 4, 2019 |
| B of A Securities | downgrade | Buy →Neutral | Nov 4, 2019 |
| Credit Suisse | upgrade | Underperform →Outperform | Sep 4, 2019 |
| Barclays | maintain | Equal Weight | Jun 11, 2019 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | May 20, 2019 |
| Jefferies | maintain | Underperform | Nov 1, 2017 |
| Morgan Stanley | upgrade | Equal Weight →Overweight | Sep 21, 2017 |
| Jefferies | downgrade | Hold →Underperform | Jul 27, 2016 |
| HSBC | downgrade | Hold →Reduce | Jul 27, 2016 |
Earnings History
Next report: Jan 22, 2027 · EPS est. $0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 23, 2026 | $0.12 | $0.10 | $910.9M | $894.9M |
| Jul 21, 2026 | $0.06 | $0.09 | $835.7M | $850.6M |
| May 11, 2026 | $0.06 | $0.09 | $785.9M | $886.6M |
| Jan 20, 2026 | $0.16 | $0.16 | $951.6M | $927.7M |
| Oct 24, 2025 | $0.19 | $0.18 | $1.00B | $979.8M |
| Jul 23, 2025 | $0.20 | $0.18 | $988.9M | $1.01B |
| May 9, 2025 | $0.22 | $0.20 | $996.2M | $978.2M |
| Jan 29, 2025 | $0.20 | $0.19 | $969.6M | $975.7M |
News
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
Dr. Reddy's Laboratories Ltd (NYSE: RDY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.92 and traded as high as $12.94. Dr. Reddy's Laboratories shares last traded at $12.7650, with a volume of 3,738,869 shares traded. Wall Street Analyst Weigh
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY)
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happ.
Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (âDr. Reddy'sâ or the âCompanyâ) (NYSE: [url="]RDY[/url]
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DR. REDDY'S LABORATORIES (RDY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal righ…